Global Human Insulin Market Size study, By Product Type (Insulin Analogs and Biosimilars (Rapid-acting, Long-acting, Premixed), Human Insulin Biologics (Short-acting, Intermediate-acting, Premixed)), By Type (Insulin Analogs and Biosimilars (Long-Acting B

Global Human Insulin Market Size study, By Product Type (Insulin Analogs and Biosimilars (Rapid-acting, Long-acting, Premixed), Human Insulin Biologics (Short-acting, Intermediate-acting, Premixed)), By Type (Insulin Analogs and Biosimilars (Long-Acting Biosimilars, Rapid-Acting Biosimilars, Premixed Biosimilars), HI Biologics (Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics)), By Delivery Devices (Pens, Pen Needles, Syringes), By Brand (Insulin Analogs and Biosimilars (Lantus, NovoRapid/Novolog, Humalog, Other Brands), Human Insulin Biologics (Actrapid, Insulatard, and Mixtard, Humulin, Insuman)), By Application (Type I Diabetes, Type II Diabetes), and Regional Forecasts 2022-2028

Global Human Insulin Market is valued approximately USD 42.30 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.1% over the forecast period 2022-2028.

Human insulin works by assisting move sugar from the blood into further body tissues where it is devoured for energy and it also prevents the liver from producing more sugar. Human insulin is manufactured through genetic engineering by injecting insulin-producing genes into bacteria. This technique has reduced the cost of manufacturing by some manifolds. The growing number of diabetic patients, increasing demand for the HI analogs, technological developments in HI delivery devices, presence of favorable medical reimbursement scenarios in various regions are the primary factors that are augmenting the market demand around the world. For instance, according to the International Diabetic Federation (IDF), in 2019, there were nearly 463 million adults aged between 20-79 years were suffering from diabetes. Also, the amount is anticipated to reach around 700 million by 2045. Consequentially, the growing prevalence of diabetes is fostering the demand for human insulin, which, in turn, accelerates market growth in the near future. However, high product manufacturing costs and stringent regulatory requirements for product approval impede the growth of the market over the forecast period of 2022-2028. Also, the development of the emerging markets and expected patent expiry of key HI drugs is anticipated to act as a catalyzing factor for the market demand during the forecast period.

The key regions considered for the global Human Insulin market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing responsiveness to benefits offered by human insulin in diabetes treatment and the presence of major market players in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as growing incidences of diabetes, as well as escalating population, would create lucrative growth prospects for the Human Insulin market across the Asia-Pacific region.

Major market players included in this report are:
Sanofi S.A.
Novo Nordisk A/S
Eli Lilly and Company
Biocon Ltd.
Julphar
Ypsomed AG
Becton, Dickinson and Company
Wockhardt Ltd.
B. Braun Meselgen AG
Biodel Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product Type:
Insulin Analogs and Biosimilars
Rapid-acting
Long-acting
Premixed
Human Insulin Biologics
Short-acting
Intermediate-acting
Premixed
By Type:
Insulin Analogs and Biosimilars
Long-Acting Biosimilars
Rapid-Acting Biosimilars
Premixed Biosimilars
HI Biologics
Short-Acting Biologics
Intermediate-Acting Biologics
Premixed Biologics
By Delivery Devices:
Pens
Pen Needles
Syringes
By Brand:
Insulin Analogs and Biosimilars
Lantus
NovoRapid/Novolog
Humalog
Other Brands
Human Insulin Biologics
Actrapid, Insulatard, and Mixtard
Humulin
Insuman
By Application:
Type I Diabetes
Type II Diabetes
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Human Insulin Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Sanofi S.A.
Novo Nordisk A/S
Eli Lilly and Company
Biocon Ltd.
Julphar
Ypsomed AG
Becton, Dickinson and Company
Wockhardt Ltd.
B. Braun Meselgen AG
Biodel Inc.